TAT 2015

Dr Brentjens (Memorial Sloan Kettering Cancer Center, New York, USA) talks to ecancertv at TAT 2015 about chimeric antigen receptor (CAR) T cell therapy, outlining how it has been used with great success to treat patients with B-cell cancers. He also discusses some of the practicalities and challenges of using this approach in clinical practice.

Prof Workman (Institute of Cancer Research, UK) talks to ecancertv at TAT 2015 about his work on the cancer genome and how this knowledge can be harnessed to help improve drug discovery and hopefully overcome resistance to molecularly targeted therapies. He also discusses his research on developing inhibitors to the heat shock protein (HSP) 90 molecular chaperone and the PI3 kinase family of signalling enzymes.

Dr Brentjens (Memorial Sloan Kettering Cancer Center, New York, USA) talks to ecancertv at TAT 2015 about chimeric antigen receptor (CAR) T cell therapy, outlining how it has been used with great success to treat patients with B-cell cancers. He also discusses some of the practicalities and challenges of using this approach in clinical practice.

Dr Shapiro (Dana Farber Cancer Institute, Boston, USA) talks to ecancertv at TAT 2015 about the roles of cyclin dependent kinase (CDK) pathways as targets for anti-cancer therapy. He describes the potential of emerging CDK inhibitors in cancer treatment, and summarises the most promising developments in this research area.

Prof Pommier (National Cancer Institute, Bethesda, USA) talks to ecancertv at TAT 2015 about the role of PARP inhibitors in targeted anticancer therapies - particularly in combination with other therapeutic agents, including DNA-targeting drugs.

Dr Plummer (Newcastle University, Newcastle, UK) talks to ecancertv about DNA repair inhibitors, the focus of the session she chaired at TAT 2015.

Prof Siu (University Health Network, Toronto, Canada) talks to ecancertv at TAT 2015 about exciting developments in immunotherapy and what the future may hold.

Professor Soria (Institut Gustave Roussy, Paris, France) talks to ecancer about mutant specific kinases including data from the TIGERX phase I/II study with rociletinib, an irreversible epidermal growth factor receptor (EGFR)-mutant selective inhibitor. As the outgoing president of the meeting, Professor Soria also provides a general overview of TAT 2015 and provides some scientific and personal highlights. He also encourages participation in TAT 2016 which will be held next year in Washington DC, USA.

Professor Calvert (UCL Cancer Institute, London, UK) talks to ecancertv about molecularly targeted drug discovery, the subject of his TAT Honorary Award Lecture 2015.

Radiogenomics should be an integral part of drug development, according to Dr Korn (CMO and founder of Imaging Endpoints, Scottsdale, USA) who talks to ecancer about this evolving field at TAT 2015. In the interview, Korn discusses how radiogenomics can be used to evaluate tumour response to molecularly targeted agents and how it improves on more traditional methods.

Prof Ribas (UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA) talks to ecancertv at TAT 2015 about adoptive T-cell therapy approaches and their current stage of clinical development. He also discusses the challenges of moving this personalised approach to cancer therapy into the clinic.

Professor Sznol (Yale Cancer Center, New Haven, USA) talks to ecancertv at TAT 2015 about his work on anti-CTLA-4 and anti-PD-1 inhibitors, which he is combining to activate the immune response against cancer.

Heat shock protein (Hsp) 90 is a ubiquitous protein that helps other proteins to fold and stabilises a number of proteins involved in tumour growth. Dr Banjerji (Institute of Cancer Research, Sutton, United Kingdom) talks to ecancertv at TAT 2015 about his experience with Hsp90 inhibitors and the practicalities of using these drugs in the clinic.